invite friends ⋅ share via emailtwitter
support the site ⋅ become a member ⋅ unscramble the egg
free120  nbme24  nbme23  nbme22  nbme21  nbme20  nbme19  nbme18  nbme17  nbme16  nbme15  nbme13 

NBME 18 Answers

nbme18/Block 1/Question#3 (34.7 difficulty score)
5 yo boy, history of motion sickness
Antagonist at muscarinic-3 receptors🔍
tags:

Login to comment/vote.


 +1  upvote downvote
submitted by iguzman2(1),
unscramble the site ⋅ become a member ($36/month)

erAnt' 1M psrocrete unodf ni teh nirba adn rea sorlsbeenpi fro mitono esksnc?is

m-ice  M1 receptors are for sure the major muscarinic receptor type found in the CNS, but M3 receptors are the muscarinic subtype involved in vomiting controlled by the CNS. This is definitely a random fact, but I think they also wanted you to eliminate all other options. Targeting the sympathetic system (options A and B) won't make a difference. NMDA receptors are a major receptor throughout the CNS, but they're not a target of antihistamines, and neither are serotonin receptors. We know that antihistamines target histamine and muscarinic receptors, but the H2 histamine receptor is responsible for gastrin secretion in the stomach, so the answer must be antagonism of M3 receptors. +4  
dorsal_vein  ^ First generation antihistamines definitely antagonize serotonin receptors within the CNS, which can cause weight gain and increase appetite. However, this plays little role in motion sickness. +5  
mumenrider4ever  That is confusing because scopolamine (anti-muscarinic used to treat motion sickness) is an M1 receptor antagonist +1  
pelparente  So according to amboss scopolamine is a nonspecific antiemetic. I think Sketchy probably just confused everyone. https://www.amboss.com/us/knowledge/Antiemetics +1  



unscramble the site ⋅ become a member ($36/month)

ibo1csn0pderl1wr11m6iay.2/l.icl4sn/e./h/yo:ftd/.1ptin18/o

4g.p of teh sutmn,paicr ttoomb itghr paahprrag

visualninjacontender  "As we know that all mAChR subtypes are expressed in the brain, while only M1, M2, and M5 exist in vestibular ganglia and vestibular end organs in humans [72]. The M1, M3, and M5 are postsynaptic excitatory receptors; M2 and M4 receptors are inhibitory. Furthermore, selective M3 and M5 antagonist zamifenacin was found to be as effective as scopolamine in preventing Motion Sickness. These lines of evidence suggest that scopolamine might exert its antagonistic effect on peripheral M1 and M5 and/or central M1 and M3 mAChR to prevent MS" +